EGFR and non-small cell lung carcinoma: Other preclinical [15] and clinical studies [16–18] showed a correlation of tumor response to EGFR inhibition in NSCLC to early reduction in SUV as assessed by FDG-PET/CT, particularly in tumors with EGFR mutations.